[HTML][HTML] Differentiation therapy of myeloid leukemia: four decades of development
V Madan, HP Koeffler - Haematologica, 2021 - ncbi.nlm.nih.gov
Acute myeloid leukemia is characterized by arrested differentiation, and agents that
overcome this block are therapeutically useful, as shown by the efficacy of all-trans retinoic …
overcome this block are therapeutically useful, as shown by the efficacy of all-trans retinoic …
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia
H Boutzen, E Saland, C Larrue, F De Toni… - Journal of Experimental …, 2016 - rupress.org
Acute myeloid leukemia (AML) is characterized by the accumulation of malignant blasts with
impaired differentiation programs caused by recurrent mutations, such as the isocitrate …
impaired differentiation programs caused by recurrent mutations, such as the isocitrate …
IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies
M Meggendorfer, LV Cappelli, W Walter, C Haferlach… - Leukemia, 2018 - nature.com
Acute myeloid leukemia (AML) is characterized by impaired hematopoiesis and bone
marrow failure caused by clonal expansion of undifferentiated myeloid precursors. The …
marrow failure caused by clonal expansion of undifferentiated myeloid precursors. The …
Towards precision medicine for AML
With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
Targeting IDH1 and IDH2 mutations in acute myeloid leukemia
BK Ragon, CD DiNardo - Current hematologic malignancy reports, 2017 - Springer
Abstract Purpose of Review Over the past decade, the pathogenic role of mutations in
isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with AML …
isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with AML …
Advances in acute myeloid leukemia: recently approved therapies and drugs in development
Simple Summary Acute myeloid leukemia (AML) is one of the most common types of
leukemia in adults, with an average first diagnosis at age 68, and has historically carried …
leukemia in adults, with an average first diagnosis at age 68, and has historically carried …
Differentiation therapy for myeloid malignancies: beyond cytotoxicity
RJ Stubbins, A Karsan - Blood Cancer Journal, 2021 - nature.com
Blocked cellular differentiation is a central pathologic feature of the myeloid malignancies,
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Treatment regimens …
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Treatment regimens …
Therapeutic targeting of isocitrate dehydrogenase mutant AML
P Boddu, G Borthakur - Expert Opinion on Investigational Drugs, 2017 - Taylor & Francis
The last decade has witnessed rapid advances in our understanding of molecular
leukemogenesis providing valuable insights from which to explore new therapeutic …
leukemogenesis providing valuable insights from which to explore new therapeutic …
Advances in acute myeloid leukemia differentiation therapy: A critical review
AK Abdel-Aziz - Biochemical Pharmacology, 2023 - Elsevier
Acute myeloid leukemia (AML) is characterized by impaired differentiation and indefinite
proliferation of abnormal myeloid progenitors. Although differentiating agents were deemed …
proliferation of abnormal myeloid progenitors. Although differentiating agents were deemed …
The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
S Nassereddine, CJ Lap, F Haroun, I Tabbara - Annals of hematology, 2017 - Springer
For decades, researchers have looked into the pathophysiology of acute myeloid leukemia
(AML). With the advances in molecular techniques, the two-hit hypothesis was replaced by a …
(AML). With the advances in molecular techniques, the two-hit hypothesis was replaced by a …